Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

IMPORTANCE: Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety risks remains unknown. OBJECTIVE: To evaluate the efficacy and safety of fingolimod, 0.5 mg, a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Neurol
Main Authors: Cree, Bruce A. C., Goldman, Myla D., Corboy, John R., Singer, Barry A., Fox, Edward J., Arnold, Douglas L., Ford, Corey, Weinstock-Guttman, Bianca, Bar-Or, Amit, Mientus, Susanne, Sienkiewicz, Daniel, Zhang, Ying, Karan, Rajesh, Tenenbaum, Nadia
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2021
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445630/
https://ncbi.nlm.nih.gov/pubmed/32852530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.2950
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker